DUBLIN–(BUSINESS WIRE)–The “Breast
Cancer Screening Test Market – Growth, Trends, and Forecast (2019 –
2024)” report has been added to ResearchAndMarkets.com’s
The breast cancer screening test market is expected to register a CAGR
of 4.5% over the forecast period.
Factors that are responsible for the growth of this market include the
increasing awareness about the early detection of breast cancer, the
growing incidence of breast cancer, and the increasing government
initiatives and support.
Early detection of breast cancer can lead to desired outcomes, including
increased survival rate, number of treatment options, and improved
quality of life – the rising incidence of breast cancer is helping the
market to grow in the forecast period. As per Breastcancer.org, about
one in eight US women (about 12.4%) will develop invasive breast cancer
over the course of their lifetime.
In 2018, an estimated 266,120 new cases of invasive breast cancer are
anticipated to be diagnosed in women only in the United States, along
with 63,960 new cases of non-invasive breast cancer. Since there is a
rising need for the breast cancer screening test across developing as
well as developed nations, the demand for breast cancer screening tests
is increasing which is leading to the growth of this market.
Key Market Trends
Imaging Test is Expected to Dominate in the Breast Cancer Screening
The most commonly used screening test for breast cancer is the imaging
test and these imaging tests are considered as the most reliable ones.
Mammograms are the most widely used tests to screen breast cancer.
Since mammography is the gold standard technique used to screen breast
cancer, governments and other healthcare organizations around the world
are taking initiatives to provide women, between the ages of 50 and 75,
access to mammography screening. This is increasing the global demand
for mammography while laboratory and blood tests and other imaging tests
are gaining popularity.
Digital breast tomosynthesis can increase the diagnostic accuracy of
mammography and is used for the assessment of equivocal or suspicious
mammography findings. Other modalities, such as ultrasound and
contrast-enhanced magnetic resonance imaging (MRI) play an important
role in the diagnostics, staging, and follow-up of breast cancer.
North America Dominates the Market and Expected to do Same in the
North America currently dominates the market for breast cancer screening
test and is expected to continue its stronghold for a few more years. In
the North American region, the United States holds the largest market
This can be majorly attributed to the increasing incidence rates of
breast cancer and rising awareness among the population for the early
detection of cancer. The presence of the developed healthcare
infrastructure is expected to propel the market in the United States.
The breast cancer screening test market is moderately competitive and
consists of several major players. In terms of market share, a few of
the major players currently dominate the market. With the increasing
awareness among the population and rising advances in the screening
test, a few other smaller players are expected to enter the market and
may come to hold a substantial share.
Some of the major players of the market are Allengers, Biocrates Life
Sciences, Myriad Genetics, Hologic, and Siemens Healthineers, among
Key Topics Covered
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness about Early Detection of Breast Cancer
4.2.2 Growing Incidence of Breast Cancer
4.2.3 Increasing Government Initiatives and Support
4.3 Market Restraints
4.3.1 Controversies Related to Mammography
4.3.2 High Cost of Screening Tests in the Developing Countries
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Test
5.1.1 Genomic Tests
18.104.22.168 MammaPrint Test
22.214.171.124 Breast Cancer Index Test
126.96.36.199 Mammostrat Test
188.8.131.52 PAM50 Test
184.108.40.206 Oncotype DX Test
220.127.116.11 Other Genomic Tests
5.1.2 Imaging Test
18.104.22.168 Other Imaging Tests
5.2.1 North America
5.2.4 Middle East & Africa
5.2.5 South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allengers Medical Systems Limited
6.1.2 Myriad Genetics
6.1.3 Agendia B.V.
6.1.4 Armune BioScience Inc.
6.1.5 Metabolomic Technologies Inc.
6.1.6 Fujifilm Holdings Corporation
6.1.7 Biocrates Life Sciences AG
6.1.8 Siemens Healthineers
6.1.9 Hologic Inc.
6.1.10 Quest Diagnostics Incorporated
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/rnym1e
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900